Navigation Links
Understanding the RNAi Reagents Market Overlap with Drug Discovery and Therapeutic Development is Critical for Pharmaceutical Leaders
Date:5/14/2012

FARMINGTON, Conn., May 14, 2012 /PRNewswire-iReach/ -- Global Information Inc. is pleased to announce two significant new reports on RNA interference (RNAi) and its relationship with peripheral markets:

RNA Interference (RNAi)

Global Industry Analysts' new RNA Interference (RNAi) market research report provides annual estimates and forecasts for drug discovery and target validation, reagents, and siRNA synthesis. This report analyzes the worldwide markets for RNA Interference (RNAi) in US$ Million, and provides separate analytics for the US, Canada, Japan, Europe, Asia-Pacific, and the Rest of the World. Annual RNAi estimates and forecasts are provided for the period 2009 through 2017. Also, a six-year historic analysis is provided. The report includes profiles of 135 companies including many key and niche players.

An Executive Summary for this report and a free sample of the full document are available at http://www.giiresearch.com/report/go240220-rna-interference-rnai.html

RNAi - technologies, markets and companies

While the most well-known use for RNAi reagents is in research, this market partially overlaps with drug discovery and therapeutic development. Areas of therapeutic applications include virus infections, cancer, genetic disorders and neurological diseases. Jain Pharmabiotech's new RNAi Market research report examines this developing category, identifying and analyzing 161 companies involved in developing RNAi technologies. Half of these supply reagents and technologies, others use the technologies for drug discovery. Out of these, 33 are developing RNAi-based therapeutics and 30 are involved in microRNAs.

Various RNAi -based products are currently in clinical trials with no marketed products to date, and many of the related patents are still pending. This report describes those RNAi technologies, along with design and methods of manufacture of siRNA reagents. These include chemical synthesis by in-vitro transcription and use of plasmid or viral vectors. Other approaches to RNAi include DNA-directed RNAi (ddRNAi) that is used to produce dsRNA inside the cell, which is cleaved into siRNA by the action of Dicer, a specific type of RNAse III. MicroRNAs are derived by processing of short hairpins that can inhibit the mRNAs. Expressed interfering RNA (eiRNA) is used to express dsRNA intracellularly from DNA plasmids.

A summary for this report and a free sample of the full document are available at http://www.giiresearch.com/report/jai70930-rnai.html

About Global Information Inc. Global Information (GII) (http://www.giiresearch.com) is an information service company partnering with over 300 research companies around the world. Global Information has been in the business of distributing technical and market research for more than 25 years. Expanded from its original headquarters in Japan, Global Information now has offices in Korea, Taiwan, Singapore, Europe and the United States.

Media Contact: Jeremy Palaia Global Information, Inc., 1-860-674-8796, Press@gii.co.jp

News distributed by PR Newswire iReach: https://ireach.prnewswire.com


'/>"/>
SOURCE Global Information, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology news :

1. Hidden infections crucial to understanding, controlling disease outbreaks
2. Proteins in sperm unlock understanding of male infertility says new study
3. Caltech scientists engineer supersensitive receptor, gain better understanding of dopamine system
4. Understanding how oxidative stress impairs endothelial progenitor cell function
5. Stowers Institutes Linheng Li Lab expands understanding of bone marrow stem cell niche
6. New technique is quantum leap forward in understanding proteins
7. Understanding extinct microbes may influence the state of modern human health
8. Understanding phosphorus in soils is vital to proper management
9. Biologist receives the 2008 AAAS Public Understanding of Science and Technology Award
10. Diminuendo -- New mouse model for understanding cause of progressive hearing loss
11. Understanding natural crop defenses
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/12/2016)... -- WearablesResearch.com , a brand of Troubadour Research ... the Q1 wave of its quarterly wearables survey. A ... to a program where they would receive discounts for ... "We were surprised to see that so ... , CEO of Troubadour Research, "primarily because there are ...
(Date:4/28/2016)... , April 28, 2016 First quarter ... (139.9), up 966% compared with the first quarter of 2015 ... totaled SEK 589.1 M (loss: 18.8) and the operating margin was ... (loss: 0.32) Cash flow from operations was SEK 249.9 ... 2016 revenue guidance is unchanged, SEK 7,000-8,500 M. The ...
(Date:4/15/2016)... 15, 2016  A new partnership announced today ... underwriting decisions in a fraction of the time ... and high-value life insurance policies to consumers without ... With Force Diagnostics, rapid testing (A1C, Cotinine and ... (blood pressure, weight, pulse, BMI, and activity data) ...
Breaking Biology News(10 mins):
(Date:6/27/2016)... CLEVELAND , June 27, 2016  Global ... average 4.6 percent through 2020 to $7.2 billion.  ... (food and beverages, cleaning products, biofuel production, animal ... and biotechnology, diagnostics, and biocatalysts). Food and beverages ... gains driven by increasing consumption of products containing ...
(Date:6/27/2016)... ... June 27, 2016 , ... Newly created 4Sight ... solutions to the healthcare market. The company's primary focus is on new product ... marketing strategies that are necessary to help companies efficiently bring their products to ...
(Date:6/24/2016)... June 24, 2016 Epic Sciences unveiled ... cancers susceptible to PARP inhibitors by targeting homologous ... (CTCs). The new test has already been incorporated ... multiple cancer types. Over 230 clinical ... response pathways, including PARP, ATM, ATR, DNA-PK and ...
(Date:6/23/2016)...   Boston Biomedical , an industry leader ... target cancer stemness pathways, announced that its lead ... Designation from the U.S. Food and Drug Administration ... gastroesophageal junction (GEJ) cancer. Napabucasin is an orally ... stemness pathways by targeting STAT3, and is currently ...
Breaking Biology Technology: